The New Class of Alzheimer's Drug Is Finally Working — Here Is What 'Working' Actually Means

Lecanemab and donanemab slow Alzheimer's progression. Here is the specific clinical benefit, the serious side effects, and the brutal economics of treating the world's most feared disease.

The FDA approval of lecanemab (Leqembi) in 2023 and donanemab (Kisunla) in 2024 represented the first time that drugs have been approved that genuinely slow the progression of Alzheimer's disease rather than merely managing symptoms. Understanding what 'slow' means in clinical terms, what it costs patients in side effects, and what it costs healthcare systems financially is essential to a balanced assessment of what these approvals actually mean for Alzheimer's patients.

The clinical benefit: in lecanemab's Phase 3 trial, the drug slowed cognitive decline by approximately 27 percent over 18 months compared to placebo. This means that patients on lecanemab deteriorated less rapidly than those on placebo — not that they improved, not that their disease stopped, but that the trajectory of decline was shallower. The clinical meaningfulness of a 27 percent slower decline — which corresponds to approximately 5 months of additional functional independence over an 18-month period — is actively debated by neurologists. Some describe it as a meaningful preservation of quality of life; others describe the benefit as below the threshold of what patients would notice in daily function.

The safety concern: amyloid-related imaging abnormalities (ARIA) — brain swelling and microbleeds detectable on MRI — occurred in approximately 35 percent of lecanemab-treated patients and 37 percent of donanemab-treated patients. Most ARIA episodes are asymptomatic or mildly symptomatic, but approximately 3 percent of ARIA events were serious and three deaths in clinical trials were attributed to ARIA-related complications. The specific risk is higher in carriers of the ApoE4 genetic variant — the most significant genetic risk factor for Alzheimer's — who constitute approximately 25 percent of the general population but approximately 65-70 percent of late-onset Alzheimer's patients.

The economic reality: lecanemab is priced at approximately $26,500 per year. Coverage requires infusion visits every two weeks plus MRI monitoring for ARIA. The full treatment protocol costs healthcare systems approximately $50,000 per patient per year, and treating the full population of people who would potentially benefit — 6-7 million Americans — would cost several hundred billion dollars annually.